Development and Function of Natural Autoreactive B Cells

Information

  • Research Project
  • 7522676
  • ApplicationId
    7522676
  • Core Project Number
    R01AI049335
  • Full Project Number
    2R01AI049335-06A2
  • Serial Number
    49335
  • FOA Number
    PA-07-70
  • Sub Project Id
  • Project Start Date
    9/30/2001 - 23 years ago
  • Project End Date
    5/31/2013 - 11 years ago
  • Program Officer Name
    NASSERI, M. FARAZ
  • Budget Start Date
    6/1/2008 - 16 years ago
  • Budget End Date
    5/31/2009 - 15 years ago
  • Fiscal Year
    2008
  • Support Year
    6
  • Suffix
    A2
  • Award Notice Date
    5/15/2008 - 16 years ago

Development and Function of Natural Autoreactive B Cells

[unreadable] DESCRIPTION (provided by applicant): Although it is widely accepted that B cells with self-reactivity are deleted or rendered functionally inactive, self-reactive antibodies, referred to as "natural autoantibodies" can be found in the serum of healthy animals. Such natural autoantibodies are produced by a small fraction of B cells with distinctive expression of the cell surface glycoprotein CD5. These CD5+ autoreactive B cells are more frequently generated from fetal B cell precursors as a part of "B-1" B cell development than those in the adult bone marrow. The importance of fetal/neonatal natural autoantibodies in protective immunity is exemplified by T15 idiotype positive anti-phosphorylcholine antibody, the most protective antibody to virulent pnuemococcal infection, rapidly produced after infection. Our research explores why such autoreactive B cells exist naturally, the mechanism whereby they develop, and their potential for dysregulation. By establishing and investigating mouse natural autoreactive B cell models expressing natural anti-Thy-1 autoantibody (ATA), we found that self-antigen is important for CD5+ ATA autoreactive B-1 B cell accumulation with relatively higher B cell receptor (BCR) signal intensity mediating a positive selection process. In contrast, negative selection occurs for cells expressing the identical BCR during conventional B cell ("B-2") development in spleen from bone marrow precursors. In this renewal, we will obtain a comprehensive understanding of the mechanism for development of this B cell subset . We will first investigate the mechanism of follicular B cell maturation and maintenance in B-2 B cell development. The significance of non-BCR signaling, provided by other lymphocytes, T cells and B-1 B cells, for the maturation of B cells that lack a BCR crosslinking signal, and a role for bacterial products in B cell survival will be examined (Aim 1). To understand why autoreactive B-1 positive selection occurs from fetal B cell development, we will identify a "fetal B-1 signature" that we hypothesize reflects distinctive cellular machinery determining a difference in the BCR signaling threshold, relative to bone marrow B-2 development. The fate of such earlygenerated B-1 cells will be examined in Lysmd2-GFP reporter mice, based on our recent identification of this gene as a component of the fetal B-1 signature (Aim 2). Accomplishing these aims will significantly advance our understanding of B cell development, and the importance of self-antigen and microenvironment in establishing a fully competent immune system. In humans, CD5 expression is a hallmark of late developing chronic B cell leukemia ( B CLL). Arriving at a comprehensive understanding of B cell development and the mechanism of their maintenance will be critically important for designing rational therapies of such dysregulated CD5+ B cells in the future. [unreadable] PUBLIC HEALTH RELLEVANCE: The immune system plays a crucial role in the acute response to infectious agents and natural autoreactive B-1 B cells play a key role in this system, rapidly producing antibodies to eradicate microorganisms. However, abnormal expansions of B-1 B cells can occur with age in certain autoimmune mouse strains, sometimes progressing to CD5+ B leukemia/lymphoma. Arriving at a comprehensive understanding of the mechanism(s) of B cell development, and establishing how natural autoreactive B-1 B cell are normally regulated and function, as proposed in this application, will be critically important both for designing rational therapies of infectious disease and for treating dysregulated B cell expansions that may lead to cancer. [unreadable] [unreadable] [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R01
  • Administering IC
    AI
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    433229
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    855
  • Ed Inst. Type
  • Funding ICs
    NIAID:433229\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    INSTITUTE FOR CANCER RESEARCH
  • Organization Department
  • Organization DUNS
    872612445
  • Organization City
    Philadelphia
  • Organization State
    PA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    191112434
  • Organization District
    UNITED STATES